Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilzabrutinib dose-finding and expansion study in relapsed immune thrombocytopenia
NL-OMON52638Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rilzabrutinib in immune thrombocytopenia (ITP) (2 arms), sponsored by Sanofi. Primary endpoints: Treatment-emergent adverse events, Sustained platelet response over final 12 weeks and 2 more. Started Feb 2020; status: recruiting.
02
Drugs
rilzabrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NL-OMON52638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52638.